• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Merlin Appoints Ryan Carrithers as Chief Financial Officer, Increasing Public Market Readiness

    11/4/25 9:00:00 AM ET
    $ASTR
    $BACQ
    $DNA
    Transportation Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ASTR alert in real time by email

    Carrithers brings to Merlin a unique blend of technical expertise, capital markets experience, and operational rigor, backed by a proven record in scaling innovative automation and aerospace companies

    Merlin Labs, Inc., a leading developer of assured, autonomous flight technology for defense customers, today appointed Ryan Carrithers as its new Chief Financial Officer. Carrithers joins Merlin at a pivotal moment as the company prepares to go public in a Business Combination with Inflection Point Acquisition Corp. IV (NASDAQ:BACQ). In this role, he will oversee all of Merlin's financial operations and strategy, investor relations, M&A or strategic partnerships that support its autonomy roadmap, and capital markets engagement as Merlin accelerates toward its public company transition.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104781512/en/

    Merlin Appoints Ryan Carrithers as Chief Financial Officer, Increasing Public Market Readiness

    Merlin Appoints Ryan Carrithers as Chief Financial Officer, Increasing Public Market Readiness

    Carrithers has over 20 years of extensive experience across aerospace, industrial, and automation companies, including American spaceflight company Astra (NASDAQ:ASTR), and global robotics and automation company KUKA. Most recently, Carrithers was the Vice President of Strategic Finance and Treasury at Ginkgo Bioworks (NYSE:DNA), proving his deep operational insight and capital markets acumen in leading the financial strategy for publicly traded companies. He brings to Merlin a strong track record in scaling complex engineering-driven businesses and domain expertise in aerospace, defense, automation, and industrial systems.

    "As Merlin enters this next chapter, we require strong financial discipline and strategic scaling as we prepare for the public markets," said Matt George, CEO and founder, Merlin. "Ryan brings the hands-on leadership experience in aerospace and high-growth technology needed to strengthen our financial strategy, maintain a strong investor base, and guide Merlin's continued growth and scale. We're thrilled to welcome him to the team at such a pivotal and growth-oriented stage in our journey."

    Merlin has already laid important groundwork ahead of its public listing with a valuation of $800 million pre-money and over $125 million of PIPE capital committed. The company continues to scale critical AI-enabled autonomous flight capabilities, is partnered with the Department of Defense for military integrations on both the KC-135 and C-130J platforms, and collaborating with leading aerospace primes like Northrop Grumman and GE Aerospace.

    "Just as digital avionics and fly-by-wire systems redefined modern aviation, Merlin is now bringing superhuman intelligence to the cockpit," said Carrithers. "By merging advanced AI with both legacy and next-generation aircraft systems, we are unlocking new flight capabilities, expanding mission profiles, and transforming aerospace economics. With more than $100 million in contracted programs, proven performance across multiple aircraft types, and deep partnerships with the U.S. Department of Defense, Northrop Grumman, and GE Aerospace, Merlin is positioned to lead this next major inflection in aerospace."

    About Merlin

    Merlin is the leading U.S.-based developer of cost-effective, takeoff-to-touchdown autonomy for both legacy and next-generation airborne systems. Our aircraft-agnostic, AI-powered software is purpose-built for military and civil programs, and is powering an expanding range of missions and aircraft, proven through hundreds of autonomous flights from test facilities across the globe. With $100M+ total in awarded contracts from military customers, Merlin is helping to solve national security challenges through safe, reliable autonomy. To learn more, visit www.merlinlabs.com or follow us on X @merlinaero.

    About Inflection Point Acquisition Corp. IV

    Inflection Point Acquisition Corp. IV is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

    Forward-Looking Statements

    Certain statements made herein are not historical facts but may be considered "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" or the negatives of these terms or variations of them or similar terminology or expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, the proposed business combination between Inflection Point Acquisition Corp. IV ("Inflection Point") and Merlin Labs, Inc. ("Merlin"), the estimated or anticipated future results and benefits of the combined company following the business combination, including the likelihood and ability of the parties to successfully consummate the business combination, future opportunities for the combined company and other statements that are not historical facts.

    These statements are based on the current expectations of Inflection Point and/or Merlin's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Inflection Point and Merlin. These statements are subject to a number of risks and uncertainties regarding Merlin's business and the business combination, and actual results may differ materially. These risks and uncertainties include, but are not limited to: general economic, political and business conditions; the inability of the parties to consummate the business combination or the occurrence of any event, change or other circumstances that could give rise to the termination of the business combination agreement; the number of redemption requests made by Inflection Point's shareholders in connection with the business combination; the outcome of any legal proceedings that may be instituted against the parties following the announcement of the business combination; the risk that the approval of the shareholders of Merlin or Inflection Point for the potential transaction is not obtained; failure to realize the anticipated benefits of the business combination, including as a result of a delay in consummating the potential transaction; the risk that the business combination disrupts current plans and operations as a result of the announcement and consummation of the business combination; the risks related to the rollout of Merlin's business and the timing of expected business milestones; the effects of competition on Merlin's business; the ability of the combined company to execute its growth strategy, manage growth profitably and retain its key employees; the ability of the combined company to obtain or maintain the listing of its securities on a U.S. national securities exchange following the business combination; costs related to the business combination; and other risks that will be detailed from time to time in filings with the U.S. Securities and Exchange Commission (the "SEC"). The foregoing list of risk factors is not exhaustive. There may be additional risks that Merlin and Inflection Point presently do not know or that Merlin and Inflection Point currently believe are immaterial that could also cause actual results to differ from those contained in forward-looking statements. In addition, forward-looking statements provide Merlin's and/or Inflection Point's expectations, plans or forecasts of future events and views as of the date of this communication. Merlin and Inflection Point anticipate that subsequent events and developments will cause their assessments to change. However, while Merlin and/or Inflection Point may elect to update these forward-looking statements in the future, Merlin and Inflection Point specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing Merlin's or Inflection Point's assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements. Nothing herein should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or results of such forward-looking statements will be achieved.

    Additional Information and Where to Find It

    The business combination will be submitted to shareholders of Inflection Point for their consideration. In connection with the business combination, Inflection Point intends to file a registration statement on Form S-4 (the "Registration Statement") with the SEC, which will include a proxy statement/prospectus and certain other related documents, which will serve as both the proxy statement to be distributed to its shareholders in connection with its solicitation for proxies for the vote by its shareholders in connection with the business combination and other matters to be described in the Registration Statement, as well as the prospectus relating to the offer and sale of the securities to be issued to Merlin's equityholders in connection with the completion of the business combination. After the Registration Statement is declared effective, Inflection Point will mail a definitive proxy statement and other relevant documents to its shareholders as of the record date established for voting on the business combination. This communication is not a substitute for the Registration Statement, the definitive proxy statement/prospectus or any other document that Inflection Point will send to its shareholders in connection with the business combination.

    INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ, WHEN AVAILABLE, THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS COMBINATION AND THE PARTIES TO THE BUSINESS COMBINATION. Investors and security holders will be able to obtain copies of these documents (if and when available) and other documents filed with the SEC free of charge at www.sec.gov. The definitive proxy statement/final prospectus (if and when available) will be mailed to shareholders of Inflection Point as of a record date to be established for voting on the business combination. Shareholders of Inflection Point will also be able to obtain copies of the proxy statement/prospectus without charge, once available, at the SEC's website at www.sec.gov

    Participants in the Solicitation

    Inflection Point and its directors, executive officers, and other members of management, and consultants, under SEC rules, may be deemed participants in the solicitation of proxies from Inflection Point's stockholders with respect to the business combination. A list of the names of those directors and executive officers and a description of their interests in Inflection Point is contained in the sections entitled "Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters" and "Directors, Executive Officers and Corporate Governance — Conflicts of Interest" of Inflection Point's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 10, 2025, and which is available free of charge at the SEC's website at www.sec.gov, and supplemented by the Current Report on Form 8-K filed with the SEC on July 11, 2025, and which is available free of charge at the SEC's website at www.sec.gov. Additional information regarding the interests of such participants will be contained in the Registration Statement when available.

    Merlin, its directors, executive officers, other members of management, and employees, under SEC rules, may be deemed participants in the solicitation of proxies of Inflection Point's shareholders in connection with the business combination. A list of the names of such directors and executive officers and information regarding their interests in the business combination will be included in the Registration Statement when available.

    No Offer or Solicitation

    This communication is for informational purposes only and is not (i) an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law nor (ii) the solicitation of any vote in any jurisdiction pursuant to the business combination or otherwise. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act. No securities commission or securities regulatory authority in the United States or any other jurisdiction has in any way passed upon the merits of the business combination or the accuracy or adequacy of this communication.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251104781512/en/

    Media Contact

    Kate Gundry

    617-842-6064

    [email protected]

    Get the next $ASTR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASTR
    $BACQ
    $DNA

    CompanyDatePrice TargetRatingAnalyst
    Ginkgo Bioworks Holdings Inc.
    $DNA
    5/15/2024Neutral → Sell
    BTIG Research
    Ginkgo Bioworks Holdings Inc.
    $DNA
    5/10/2024Mkt Perform → Underperform
    William Blair
    Ginkgo Bioworks Holdings Inc.
    $DNA
    11/14/2023$3.50 → $2.50Outperform → Mkt Perform
    Raymond James
    Ginkgo Bioworks Holdings Inc.
    $DNA
    11/9/2023Buy → Neutral
    BTIG Research
    Ginkgo Bioworks Holdings Inc.
    $DNA
    6/2/2023$3.00 → $1.25Neutral → Sell
    Goldman
    Ginkgo Bioworks Holdings Inc.
    $DNA
    5/11/2023Outperform → Mkt Perform
    William Blair
    Astra Space Inc.
    $ASTR
    2/2/2023$2.00 → $1.00Buy → Hold
    Deutsche Bank
    Ginkgo Bioworks Holdings Inc.
    $DNA
    11/29/2022$6.00Buy
    Berenberg
    More analyst ratings

    $ASTR
    $BACQ
    $DNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ginkgo Bioworks downgraded by BTIG Research

    BTIG Research downgraded Ginkgo Bioworks from Neutral to Sell

    5/15/24 7:33:13 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks downgraded by William Blair

    William Blair downgraded Ginkgo Bioworks from Mkt Perform to Underperform

    5/10/24 7:33:29 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks downgraded by Raymond James with a new price target

    Raymond James downgraded Ginkgo Bioworks from Outperform to Mkt Perform and set a new price target of $2.50 from $3.50 previously

    11/14/23 9:04:22 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASTR
    $BACQ
    $DNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Coen Steven P. converted options into 2,547 shares and sold $17,907 worth of shares (1,312 units at $13.65), increasing direct ownership by 22% to 6,738 units (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    10/21/25 4:56:24 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Coen Steven P. sold $84,135 worth of shares (5,609 units at $15.00), decreasing direct ownership by 50% to 5,503 units (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    10/3/25 5:01:10 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Henry Christian O sold $219,800 worth of shares (20,000 units at $10.99), decreasing direct ownership by 45% to 24,310 units (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    9/10/25 4:06:35 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASTR
    $BACQ
    $DNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sankar Shyam bought $514,750 worth of shares (625,000 units at $0.82), increasing direct ownership by 36% to 2,356,874 units (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    5/16/24 5:08:50 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sloan Harry bought $271,815 worth of shares (297,619 units at $0.91), increasing direct ownership by 71% to 718,540 units (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    5/14/24 5:16:23 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stanford Scott bought $22,315 worth of shares (18,442 units at $1.21) (SEC Form 4)

    4 - Astra Space, Inc. (0001814329) (Issuer)

    12/28/23 4:11:34 PM ET
    $ASTR
    Transportation Services
    Consumer Discretionary

    $ASTR
    $BACQ
    $DNA
    SEC Filings

    View All

    SEC Form 425 filed by Inflection Point Acquisition Corp. IV

    425 - INFLECTION POINT ACQUISITION CORP. IV (0002028707) (Subject)

    11/4/25 9:09:42 AM ET
    $BACQ

    SEC Form 425 filed by Bleichroeder Acquisition Corp. I

    425 - INFLECTION POINT ACQUISITION CORP. IV (0002028707) (Subject)

    10/28/25 9:26:51 AM ET
    $BACQ

    SEC Form 425 filed by Bleichroeder Acquisition Corp. I

    425 - INFLECTION POINT ACQUISITION CORP. IV (0002028707) (Subject)

    10/22/25 4:45:01 PM ET
    $BACQ

    $ASTR
    $BACQ
    $DNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Merlin Appoints Ryan Carrithers as Chief Financial Officer, Increasing Public Market Readiness

    Carrithers brings to Merlin a unique blend of technical expertise, capital markets experience, and operational rigor, backed by a proven record in scaling innovative automation and aerospace companies Merlin Labs, Inc., a leading developer of assured, autonomous flight technology for defense customers, today appointed Ryan Carrithers as its new Chief Financial Officer. Carrithers joins Merlin at a pivotal moment as the company prepares to go public in a Business Combination with Inflection Point Acquisition Corp. IV (NASDAQ:BACQ). In this role, he will oversee all of Merlin's financial operations and strategy, investor relations, M&A or strategic partnerships that support its autonomy road

    11/4/25 9:00:00 AM ET
    $ASTR
    $BACQ
    $DNA
    Transportation Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks Awarded Project Agreement through BARDA's BioMaP-Consortium

    Ginkgo and Partners to Develop Monoclonal Antibody Biomanufacturing Innovations and to Produce an Anti-Filovirus Medical Countermeasure BOSTON, Nov. 3, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA) announced today that it has been awarded a contract through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to develop innovations that strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies (mAbs) to protect against and treat infection by filoviruses such as Ebola (EBOV) and Sudan Viruses (SUDV).

    11/3/25 8:00:00 AM ET
    $DCI
    $DNA
    Pollution Control Equipment
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks and Bayer Extend Multi-Year Strategic Partnership to Accelerate Next Generation Biological Solutions for Agriculture

    BOSTON, Oct. 31, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA) today announced that the company has extended its multi-year strategic partnership with Bayer to advance research and development of biological products for agriculture. With the extension of this partnership, which began in 2017, both parties will build on the success of their ongoing collaboration to develop innovative microbial nitrogen fixation. As with the original agreement, Bayer retains the right to commercialize the resulting biological products as a complement to synthetic fertilizers in the coming years.

    10/31/25 8:00:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASTR
    $BACQ
    $DNA
    Financials

    Live finance-specific insights

    View All

    Ginkgo Bioworks Announces Date of Third Quarter 2025 Results Presentation

    Presentation and Q&A session scheduled for post-market on Thursday, November 6, 2025 BOSTON, Oct. 30, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2025, on Thursday, November 6, 2025, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available. To ask a question ah

    10/30/25 4:05:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks Reports Second Quarter 2025 Financial Results

    Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets BOSTON, Aug. 7, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2025. The update, including a webcast slide presentation with additional details on the second quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com. Second Quarter 2025 Fina

    8/7/25 5:01:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks Announces Date of Second Quarter 2025 Results Presentation

    Presentation and Q&A session scheduled for post-market on Thursday, August 7, 2025 BOSTON, July 31, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgob

    7/31/25 8:01:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASTR
    $BACQ
    $DNA
    Leadership Updates

    Live Leadership Updates

    View All

    Merlin Appoints Ryan Carrithers as Chief Financial Officer, Increasing Public Market Readiness

    Carrithers brings to Merlin a unique blend of technical expertise, capital markets experience, and operational rigor, backed by a proven record in scaling innovative automation and aerospace companies Merlin Labs, Inc., a leading developer of assured, autonomous flight technology for defense customers, today appointed Ryan Carrithers as its new Chief Financial Officer. Carrithers joins Merlin at a pivotal moment as the company prepares to go public in a Business Combination with Inflection Point Acquisition Corp. IV (NASDAQ:BACQ). In this role, he will oversee all of Merlin's financial operations and strategy, investor relations, M&A or strategic partnerships that support its autonomy road

    11/4/25 9:00:00 AM ET
    $ASTR
    $BACQ
    $DNA
    Transportation Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

    DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

    10/21/25 8:05:00 AM ET
    $CRVS
    $DNA
    $EXEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Ginkgo Automation Appoints Brian O'Sullivan as Head of Commercial to Accelerate External Growth

    Seasoned life‑science executive to spearhead global go‑to‑market strategy as Ginkgo Automation scales external sales across biopharma, techbio, and new science‑driven markets while continuing to support internal programs. BOSTON, Aug. 12, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced the appointment of Brian O'Sullivan as Head of Commercial for Ginkgo Automation. Brian joins Ginkgo Automation from HighRes Biosolutions, where he led their commercial efforts. In his new role, Brian wi

    8/12/25 8:01:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASTR
    $BACQ
    $DNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

    SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    11/14/24 4:31:49 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

    SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    11/12/24 3:58:52 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

    SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    11/4/24 11:56:06 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care